SIBN

Over the past six months, SI-BONE's stock has been impacted by several events. The Q1 2026 earnings report in May 2026 showed an 11.2% year-over-year revenue increase and improved adjusted EBITDA, leading to a 19.7% stock surge. The Q2 2026 earnings report in August 2026, despite beating estimates with a 15.2% revenue increase and a 178% rise in adjusted EBITDA, saw shares fall 10.29% due to investor focus on Q3 seasonality and R&D investment. In September 2026, the company received FDA 510(k) clearance for its iFuse Granite Onyx System. Effective October 2026, CMS finalized a new MS-DRG family providing higher payments for complex spinal fusion procedures incorporating iFuse Bedrock Granite. In early October 2026, COO and CFO Anshul Maheshwari sold 5,049 shares for approximately $94,078. Overall, the stock delivered a strong 51% return over the past six months, with analysts giving a 'Moderate Buy' rating and an average price target of $24.17.